| Thomas Winter, MD | |
|
3601 W. 13 Mile Rd, Royal Oak, MI 48073-6769 | |
| (248) 423-2481 | |
| Not Available |
| Full Name | Thomas Winter |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 18 Years |
| Location | 3601 W. 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053511527 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 4301090830 (Michigan) | Secondary |
| 207P00000X | Emergency Medicine | 43089 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| John C. Lincoln North Mountain Hospital | Phoenix, AZ | Hospital |
| Honorhealth Deer Valley Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Loop 101 Emergency Physicians Llc | 0840295481 | 41 |
| Cep America- Arizona, Pc | 1850541970 | 58 |
| 303 Emergency Physicians Pllc | 2567692528 | 46 |
| Emcare - Pnx Emergency Physicians Llc | 3779574165 | 36 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Honorhealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801092564 PECOS PAC ID: 1456258607 Enrollment ID: O20031216000350 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Progressive Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548218613 PECOS PAC ID: 7113829599 Enrollment ID: O20040308001331 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Scottsdale Emergency Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083671432 PECOS PAC ID: 3274425970 Enrollment ID: O20040326001331 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Emcare - Pnx Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902855992 PECOS PAC ID: 3779574165 Enrollment ID: O20040524000667 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Loop 101 Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376573378 PECOS PAC ID: 0840295481 Enrollment ID: O20061003000466 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Emergency Physicians Southwest Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912053752 PECOS PAC ID: 2264538529 Enrollment ID: O20070502000382 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Quantum Healthcare Medical Associates Of Arizona Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821391269 PECOS PAC ID: 5597946350 Enrollment ID: O20110228000065 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | Cep America- Arizona, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780202804 PECOS PAC ID: 1850541970 Enrollment ID: O20121026000403 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Entity Name | 303 Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518398585 PECOS PAC ID: 2567692528 Enrollment ID: O20140313001083 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Winter, MD 3601 W. 13 Mile Rd, Royal Oak, MI 48073-6769 Ph: (248) 423-2481 | Thomas Winter, MD 3601 W. 13 Mile Rd, Royal Oak, MI 48073-6769 Ph: (248) 423-2481 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.
The combined supercomputing power of the UK and US 'national grids' has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus.
A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.
A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).
› Verified 2 days ago
Amit Bahl, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, William Beaumont Hospital, Royal Oak, MI 48073 Phone: 248-898-0575 Fax: 248-898-4671 | |
Dr. Kjerstin Hensley, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-5000 | |
Raymond Jackson, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3601 W 13 Mile Rd, Ec, Royal Oak, MI 48073 Phone: 248-898-2015 | |
David Poleski, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3601 W 13 Mile Rd, Ec, Royal Oak, MI 48073 Phone: 248-898-2934 | |
Dr. Amy Smark, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Department Of Emergency Medicine, Royal Oak, MI 48073 Phone: 248-898-1968 | |
Dr. Yamen Nackoud, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 715 Butternut Ave, Royal Oak, MI 48073 Phone: 818-486-1511 | |
Dr. Christopher S Seitz, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-2001 |